Oral peptide delivery platform

Class

Oral-delivery reformulation technology

Peptide drugs such as GLP-1 receptor agonists are normally given by injection because peptides are large, water-soluble molecules that are rapidly broken down by digestive enzymes in the stomach and intestine and cannot easily cross the intestinal lining into the bloodstream. Oral peptide delivery platforms are formulation technologies designed to overcome these two barriers so that a peptide can be swallowed as a tablet or capsule and still reach circulation in a therapeutically meaningful amount. Approaches generally combine protection of the peptide from proteolytic degradation with a means of transiently increasing its passage across the intestinal epithelium, often by co-formulating the peptide with absorption-enhancing excipients, lipid carriers, or local pH-modifying agents. The biological rationale for pursuing oral delivery is largely about patient experience and treatment adherence rather than changing what the peptide does once absorbed; the drug's pharmacological target and downstream effects remain the same as the injectable form. This class of technology matters broadly across chronic disease areas where peptide therapeutics are used long-term, such as metabolic and endocrine conditions, because removing the need for injections can lower a practical barrier to consistent use. The main scientific challenge across all such platforms is achieving reproducible, adequate absorption despite substantial day-to-day variability in gastrointestinal conditions.